Jakafi (ruxolitinib)

News alerts, weekly reports and conference planners

Company:

Incyte, Novartis

Drug class:

JAK2 inhibitor, JAK1 inhibitor

Related drugs:

IL7R mutation	Childhood B Acute Lymphoblastic Leukemia	IL7R mutation	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
SH2B3 alteration	Childhood B Acute Lymphoblastic Leukemia	SH2B3 alteration	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	CRLF2 rearrangement + JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
EPOR rearrangement	Childhood B Acute Lymphoblastic Leukemia	EPOR rearrangement	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	JAK2 fusion	Childhood B Acute Lymphoblastic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
RUNX1 mutation	Myelodysplastic Syndrome	RUNX1 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
SETBP1 mutation	Myelodysplastic Syndrome	SETBP1 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
CBL mutation	Myelodysplastic Syndrome	CBL mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
NRAS mutation	Myelodysplastic Syndrome	NRAS mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
ASXL1 mutation	Myelodysplastic Syndrome	ASXL1 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
SRSF2 mutation	Myelodysplastic Syndrome	SRSF2 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
TET2 mutation	Myelodysplastic Syndrome	TET2 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
ETNK1 mutation	Myelodysplastic Syndrome	ETNK1 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
No biomarker	Prolymphocytic Leukemia	No biomarker	Prolymphocytic Leukemia	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
IL7R mutation	Acute Lymphocytic Leukemia	IL7R mutation	Acute Lymphocytic Leukemia	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2
SH2B3 deletion	Acute Lymphocytic Leukemia	SH2B3 deletion	Acute Lymphocytic Leukemia	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2
CRLF2 rearrangement	Acute Lymphocytic Leukemia	CRLF2 rearrangement	Acute Lymphocytic Leukemia	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2
JAK2 mutation	Acute Myelogenous Leukemia	JAK2 mutation	Acute Myelogenous Leukemia	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2
JAK2 mutation	Leukemia	JAK2 mutation	Leukemia	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2	ruxolitinib Sensitive: C2 – Inclusion Criteria ruxolitinib Sensitive : C2
CRLF2 rearrangement	Acute Lymphocytic Leukemia	CRLF2 rearrangement	Acute Lymphocytic Leukemia	T-lymphocyte cell therapy + ruxolitinib Sensitive: C2 – Inclusion Criteria T-lymphocyte cell therapy + ruxolitinib Sensitive : C2	T-lymphocyte cell therapy + ruxolitinib Sensitive: C2 – Inclusion Criteria T-lymphocyte cell therapy + ruxolitinib Sensitive : C2
CSF3R T618I	Chronic Neutrophilic Leukemia	CSF3R T618I	Chronic Neutrophilic Leukemia	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3
CSF3R T618I	Chronic Myeloid Leukemia	CSF3R T618I	Chronic Myeloid Leukemia	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + ruxolitinib Sensitive: C3 – Early Trials trastuzumab + ruxolitinib Sensitive : C3	trastuzumab + ruxolitinib Sensitive: C3 – Early Trials trastuzumab + ruxolitinib Sensitive : C3
RPS6 underexpression	Peripheral T-cell Lymphoma	RPS6 underexpression	Peripheral T-cell Lymphoma	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3
RPS6 underexpression	Cutaneous T-cell Lymphoma	RPS6 underexpression	Cutaneous T-cell Lymphoma	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3	ruxolitinib Sensitive: C3 – Early Trials ruxolitinib Sensitive : C3
EGFR T790M	Non Small Cell Lung Cancer	EGFR T790M	Non Small Cell Lung Cancer	afatinib + ruxolitinib Sensitive: C3 – Early Trials afatinib + ruxolitinib Sensitive : C3	afatinib + ruxolitinib Sensitive: C3 – Early Trials afatinib + ruxolitinib Sensitive : C3
JAK2 underexpression	Cutaneous Melanoma	JAK2 underexpression	Cutaneous Melanoma	ruxolitinib Resistant: C3 – Early Trials ruxolitinib Resistant : C3	ruxolitinib Resistant: C3 – Early Trials ruxolitinib Resistant : C3
Chr del(5q)	Acute Myelogenous Leukemia	Chr del(5q)	Acute Myelogenous Leukemia	venetoclax + ruxolitinib Resistant: C3 – Early Trials venetoclax + ruxolitinib Resistant : C3	venetoclax + ruxolitinib Resistant: C3 – Early Trials venetoclax + ruxolitinib Resistant : C3
Chr t(15;17)/PML-RARA fusion	Acute Myelogenous Leukemia	Chr t(15;17)/PML-RARA fusion	Acute Myelogenous Leukemia	venetoclax + ruxolitinib Resistant: C3 – Early Trials venetoclax + ruxolitinib Resistant : C3	venetoclax + ruxolitinib Resistant: C3 – Early Trials venetoclax + ruxolitinib Resistant : C3
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + ruxolitinib Sensitive: C3 – Early Trials venetoclax + ruxolitinib Sensitive : C3	venetoclax + ruxolitinib Sensitive: C3 – Early Trials venetoclax + ruxolitinib Sensitive : C3

Jakafi (ruxolitinib)

Associations
(73)

Associations
(73)

Jakafi (ruxolitinib)

Associations(73)

Associations(73)

Associations
(73)

Associations
(73)